期刊文献+

乳腺癌细胞ret基因转录水平的表达及其与PI3KAktmTOR信号通路相关因子的关系 被引量:1

下载PDF
导出
摘要 目的探讨乳腺癌细胞ret基因转录水平的表达及其与PI3KAktmTOR信号通路相关因子的关系。方法以乳腺癌细胞为研究对象,采用荧光定量聚合酶链式反应(RT-PCR)检测细胞中RET、PI3K、mTOR和AKT mRNA表达量,构建合成ret shRNA慢病毒载体,转染乳腺癌细胞,再次采用RT-PCR检测细胞中RET、PI3K、mTOR和AKT mRNA表达量。比较转染前后细胞中RET、PI3K、mTOR和AKT mRNA表达量,并采用Pearson线性相关分析法分析其细胞中RET mRNA表达量与其PI3K、mTOR和AKT mRNA表达量的关系。结果转染前细胞中RET、PI3K、mTOR和AKT mRNA表达量分别为0.851±0.126、0.872±0.126、0.845±0.087和0.769±0.355,均分别高于转染后的0.108±0.023、0.113±0.022、0.098±0.022和0.072±0.013(P<0.05)。Pearson线性相关分析结果显示,细胞中RET mRNA表达量与其PI3K、mTOR和AKT mRNA表达量均呈正相关(r=0.877、0.852、0.863,P<0.05)。结论乳腺癌细胞ret基因转录水平较高且与PI3KAktmTOR信号通路相关因子密切相关,可能通过调控PI3KAktmTOR信号通路而影响乳腺癌的发生发展,可能作为乳腺癌治疗的靶基因之一。
出处 《实用临床医学(江西)》 CAS 2017年第6期43-45,108,共4页 Practical Clinical Medicine
  • 相关文献

参考文献7

二级参考文献118

  • 1Vrdoljak E, Mise BP, Lukic B, et al. Long-lasting control of triple?negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine-case report. Onkologie, 2010, 3: 53-56.
  • 2Perou CM, Sorlie T, Eisen MB, et al. Molecular pomaits of human breost tumoum. Nature, 2000,406:747-752.
  • 3Wolff AC, Hammond ME, Schwartz IN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 2007,131 :1843.
  • 4Park S, Koo JS, Kim MS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast, 2012, 21: 50-57.
  • 5Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109 :25-32.
  • 6Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical cbaracterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 2004, 10:5367-5374.
  • 7Banerjee S, Reis-FIlho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol, 2006, 59 :729-735.
  • 8Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol, 2012, 30: 1879-1887.
  • 9Hernandez-Aya LF, Chavez-Macgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triple?negative breast cancer. J Clin Oncol, 2011 , 29 :2628-2634.
  • 10TIschkowitz M, Brunet JS, Begin LR, et al. Use of inrnunolristochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 2007 , 7: 134.

共引文献222

同被引文献8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部